Sign up to access all valuation multiples
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
2020
63
Last FY Revenue $0.3M
Last FY EBITDA -$145M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Atai Beckley reported revenue of $0.3M and EBITDA of -$145M.
Atai Beckley expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Atai Beckley valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $0.3M | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$145M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -47016% | XXX | XXX | XXX |
| EBIT | XXX | -$102M | XXX | XXX | XXX |
| EBIT Margin | XXX | -33171% | XXX | XXX | XXX |
| Net Profit | XXX | -$149M | XXX | XXX | XXX |
| Net Margin | XXX | -48464% | XXX | XXX | XXX |
| Net Debt | XXX | $6.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Atai Beckley has current market cap of $1.4B, and EV of $1.3B.
As of November 25, 2025, Atai Beckley's stock price is $4.
See Atai Beckley trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.4B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAtai Beckley's trades at 4171.5x EV/Revenue multiple, and -8.9x EV/EBITDA.
See valuation multiples for Atai Beckley and 15K+ public compsAs of November 25, 2025, Atai Beckley has market cap of $1.4B and EV of $1.3B.
Equity research analysts estimate Atai Beckley's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Atai Beckley's P/E ratio is not available.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.4B | XXX | $1.4B | XXX | XXX | XXX |
| EV (current) | $1.3B | XXX | $1.3B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 4171.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -8.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -12.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -9.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -15.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAtai Beckley's revenue per employee in the last FY averaged $5K, while opex per employee averaged $1.6M for the same period.
Atai Beckley's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Atai Beckley's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Atai Beckley and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -47016% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $5K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 18005% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 33271% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Atai Beckley acquired XXX companies to date.
Last acquisition by Atai Beckley was XXXXXXXX, XXXXX XXXXX XXXXXX . Atai Beckley acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Atai Beckley founded? | Atai Beckley was founded in 2020. |
| Where is Atai Beckley headquartered? | Atai Beckley is headquartered in United States of America. |
| How many employees does Atai Beckley have? | As of today, Atai Beckley has 63 employees. |
| Who is the CEO of Atai Beckley? | Atai Beckley's CEO is Mr. Srinivas G. Rao, M.D.,PhD. |
| Is Atai Beckley publicy listed? | Yes, Atai Beckley is a public company listed on NAS. |
| What is the stock symbol of Atai Beckley? | Atai Beckley trades under ATAI ticker. |
| When did Atai Beckley go public? | Atai Beckley went public in 2021. |
| Who are competitors of Atai Beckley? | Similar companies to Atai Beckley include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Atai Beckley? | Atai Beckley's current market cap is $1.4B |
| Is Atai Beckley profitable? | Yes, Atai Beckley is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
